These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 29330212)

  • 21. Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study.
    Tan RYC; Ong WS; Lee KH; Park S; Iqbal J; Park YH; Lee JE; Yu JH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Koh J; Han W; Im SA; Tan VKM; Phyu N; Wong FY; Tan PH; Yap YS
    J Natl Compr Canc Netw; 2024 May; 22(2 D):. PubMed ID: 38744306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.
    Zell JA; Tsang WY; Taylor TH; Mehta RS; Anton-Culver H
    Breast Cancer Res; 2009; 11(1):R9. PubMed ID: 19228416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgical Management of Breast Cancer in 2010-2011 SEER Registries by Hormone and HER2 Receptor Status.
    Lizarraga I; Schroeder MC; Weigel RJ; Thomas A
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S566-72. PubMed ID: 25956579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
    Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
    BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators.
    Song Y; Liu X; Zhang G; Song H; Ren Y; He X; Wang Y; Zhang J; Zhang Y; Sun S; Liang X; Sun Q; Pang D
    World J Surg Oncol; 2013 Jun; 11():129. PubMed ID: 23738706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical features and prognosis of patients with mucinous breast carcinoma compared with those with infiltrating ductal carcinoma: a population-based study.
    Zhou X; Zheng Z; Li Y; Zhao W; Lin Y; Zhang J; Sun Q
    BMC Cancer; 2021 May; 21(1):536. PubMed ID: 33975551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
    Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
    Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
    Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
    Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database.
    Wang XX; Jiang YZ; Liu XY; Li JJ; Song CG; Shao ZM
    Oncotarget; 2016 Apr; 7(16):22665-73. PubMed ID: 27009810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Nomogram for Predicting Survival Outcomes in Early Mucinous Breast Cancer.
    Fu J; Wu L; Jiang M; Li D; Jiang T; Hong Z; Wang F; Li S
    PLoS One; 2016; 11(10):e0164921. PubMed ID: 27760180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive micropapillary carcinoma of the breast has a better long-term survival than invasive ductal carcinoma of the breast in spite of its aggressive clinical presentations: a comparison based on large population database and case-control analysis.
    Chen H; Wu K; Wang M; Wang F; Zhang M; Zhang P
    Cancer Med; 2017 Dec; 6(12):2775-2786. PubMed ID: 29072365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series.
    McCormack VA; Joffe M; van den Berg E; Broeze N; Silva Idos S; Romieu I; Jacobson JS; Neugut AI; Schüz J; Cubasch H
    Breast Cancer Res; 2013; 15(5):R84. PubMed ID: 24041225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
    Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
    Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Prognostic Significance of the Oncotype DX Recurrence Score in T
    Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
    Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified.
    Cao AY; He M; Huang L; Shao ZM; Di GH
    World J Surg Oncol; 2013 Apr; 11():91. PubMed ID: 23607710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.